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ABSTRACT
Introduction: Vernal keratoconjunctivis (VKC)
is a severe form of pediatric ocular allergy,
characterized by acute and chronic
corneoconjunctival inflammation that may
lead to visual sequelae. Although topical
immunosuppressive drugs such as cyclosporine
are usually effective, some severe forms may be
refractory and require prolonged steroid
therapy. Very few papers report the use of
omalizumab in VKC in the literature. In the
present study, we describe our clinical
experience with omalizumab in severe VKC
children.
Methods: We retrospectively reviewed the files
of four boys treated with omalizumab because
of severe VKC, defined as persistent corneal
inflammation despite continuous topical 2%
cyclosporine and steroid eye drops. We also
performed a literature review.
Results: Four boys, aged 7–13 years old, were
treated. All children had asthma and one had
severe lid eczema. Two patients had required
intrapalpebral depot-steroid injections.
Omalizumab was administered every 2 weeks
by subcutaneous injections, at doses varying
from 450 to 600 mg per injection. Three
patients out of four responded to the
treatment, with a decrease in global symptoms
(median symptom rating decreasing from 89 to
29 on a 100-mm visual analog scale), frequency
and in duration of the inflammatory flares, and
also a decreased need for topical steroid. Their
median clinical grade decreased from 4 to 3
(Bonini grading). However, the response was
incomplete and they still had inflammatory
corneoconjunctival flares despite continuous
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topical cyclosporine. On the other hand,
asthma and lid eczema were completely
controlled in these three patients. The fourth
child did not respond to omalizumab and
needed oral steroids for his VKC and his
asthma. Noticeably, this latter patient did not
have detectable sensitization to any allergen,
contrary to the other cases. The treatment was
stopped in this refractory case, but is still
ongoing in all other cases, with a median
duration of 33 months (range 16–42 months).
In the literature (four cases), omalizumab may
have a more complete efficacy in some cases,
but the results are still variable.
Conclusion: Omalizumab is an interesting
treatment in severe refractory forms of VKC,
but its efficacy is incomplete in these very severe
cases.
Keywords: Children; Cyclosporine; IgE;
Immunomodulation; Severe allergy; Steroids;
VKC
INTRODUCTION
Vernal keratoconjunctivitis (VKC) is a severe
form of ocular allergy occurring mainly in
children. It is characterized by chronic
corneoconjunctival inflammation with giant
conjunctival tarsal papillae and/or limbal
inflammation. Inflammatory flares are more
frequent during the hot season, usually from
March to October in temperate climates, but
may be perennial in sunny/tropical climates or
late forms. Symptoms such as ocular itching,
burning, photophobia and sticky eyes with
mucous ropy discharge, have an important
impact on the quality of life of the children.
Furthermore, corneal involvement such as
dense superficial punctate keratitis, shield
ulcers and vernal plaques, are very
symptomatic and may lead to neovascularized
scars and visual sequelae.
Treatment of mild forms of VKC include
wearing of sunglasses, ocular rinsing with
balanced saline solution, and topical and
systemic antihistamines H1 and topical mast
cell stabilizers. In case of inflammatory flare
with corneal involvement, topical steroids are
needed. Dependence on steroids is very
frequent, exposing children to
unacceptable adverse effects such as ocular
hypertension, glaucoma, cataract and
infection. Besides, children are more
susceptible to develop ocular hypertension
than adults, and, also, monitoring of the
ocular pressure may be difficult in non
cooperative children. Topical
immunosuppressive drugs are usually used in
steroid-dependant cases. Cyclosporine A eye
drops (0.5–2%; CsA) are the most frequently
used and studied, and have been shown to have
a steroid sparing effect with an excellent safety
profile. However, a significant proportion of
patients are intolerant to CsA, and 16% and 5%
do not respond to this treatment at month 1
and 3, respectively [1]. There are very few
options in these refractory cases: supratarsal
steroid injections are very potent, but may
induce severe iatrogenic complications [2];
systemic steroids may be used only for a
limited time; tacrolimus 0.03% skin ointment
is not approved for conjunctival application,
although it seems to have a very interesting
effect [3]; tacrolimus 0.1% eye drops are
probably also potent, but are available only in
few asian countries for the moment [4]; mild
cryotherapy of papillae is also an option for
some [5], but we believe that there is a risk of
conjunctival atrophy and scarring after repeated
applications.
The pathophysiology of VKC combines
IgE-mediated allergic reactions to
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non-IgE-mediated reactions [6]. IgE-mediated
reactions characterize the classical immediate
allergic reaction, also called anaphylaxis. As a
prerequisite, sensitization to specific allergens
such as pollen, dust mites, animal dander,
mold, food allergens, leads to the production
of specific immunoglobulins E (IgEs). When the
allergen binds to specific IgEs present at the
surface of a conjunctival mast cell, a
degranulation of preformed mediators such as
histamine, chymase and tryptase by the mast
cell occurs. These mediators are responsible for
the classical symptoms and signs of the early
allergic phase: itching, redness and edema. A
late phase occurs after 6 h, as a result of the
production of postformed inflammatory
mediators such as leukotrienes and
prostaglandins by the mast cell, leading to the
infiltration of eosinophils, neutrophils and
macrophages in the tissue. Eosinophils play a
major role in inflammation and in tissular
lesions such as epitheliopathy in VKC. CD4?
TH2 cells seem to drive these IgE-dependant
reactions in VKC [7]. However, only 50% of
VKC patients have identified sensitization to
specific allergens. Indeed, several types of
non-IgE-mediated reactions also occur in VKC,
among which direct activation of T cells,
dendritic cells, enzymatic systems,
metalloproteases, and non-specific
hyper-reactivity are included [8].
Omalizumab is a monoclonal chimeric
anti-IgE antibody that binds to the Ce3
domain of free circulating IgE, resulting in
inactive immune complexes that are cleared
from the plasma [9]. It can reduce circulating
free IgE up to 99%, thus suppressing the
activation of mast cells [10] and
down-regulating the expression of the IgE
receptors FceRI at the surface of basophiles and
mast cells. Hence, the IgE-mediated reactions
are less likely to occur [11].
Several studies have shown the efficacy of
omalizumab in allergic asthma since the initial
publications in 1999 [12], leading to the
approval of omalizumab for this indication in
the USA in 2003 and in France in 2006. In
patients with moderate to severe allergic asthma
with dependence on inhaled steroids, the
addition of omalizumab reduces asthma
exacerbations and decreases inhaled
corticosteroid and rescue medication use.
Furthermore, a few studies have shown the
efficacy of this molecule in seasonal allergic
rhinitis [13, 14].
Omalizumab is administered systematically
by subcutaneous injections every 2–4 weeks,
according to the weight and the level of blood
total IgEs. It has initially been authorized for the
treatment of severe asthma. Few case reports
suggest its efficacy in VKC and atopic
keratoconjunctivitis [15, 16]. The purpose of
this study is to report our clinical experience
with omalizumab in severe refractory cases of
VKC in children, and to review the literature.
METHODS
Design
This was a non-controlled, open-label,
retrospective case series.
We reviewed the files of four boys (eight
eyes), suffering from severe VKC, and who were
treated with omalizumab.
For each patient, we collected the ocular and
extra-ocular data concerning their allergic
diseases.
At each visit, a global symptom score was
assessed by a visual analog scale (from 0 if no
symptoms to 100 mm if maximum symptoms).
VKC severity was graded according to
Bonini’s classification [17]: grade 0: no
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symptoms, no superficial punctate keratitis
(SPK); grade 1: mild symptoms, no SPK; grade
2: photophobia, no SPK; grade 3: photophobia,
moderate SPK; grade 4: photophobia, severe SPK
or corneal ulcer.
Response to treatment was graded as follows:
total control: no inflammatory flare; partial
control: decrease in the number and/or
intensity of the inflammatory flares; failure: no
change in the evolution.
The retrospective analysis was approved by
the institutional ethical committee of
Fondation A de Rothschild. The parents
provided written informed consent for
publication of clinical data.
RESULTS
Patients were aged 7–13 years. They all suffered
from very severe VKC, with symptom scores
ranging from 72 to 100 mm, and a clinical grade
of 4 in all cases, according to Bonini’s
classification. Their disease was resistant to
topical steroids and topical cyclosporine 2%
eye drops, with persistent superficial punctate
keratitis despite these treatments for more than
2 years (at least 8 months per year; Table 1).
Patient #2 developed a shield ulcer on the left
eye, requiring corneal scraping 2 years earlier. In
patients #2 and 4, supratarsal depot
triamcinolone injections had even been
performed once a year for the 2 previous years,
and were the only way to control corneal
inflammation at this moment.
All patients suffered from asthma, and also
from severe rhinitis in three cases (#1, 2 and 3)
and severe atopic dermatitis with periocular
involvement in case #3. All patients were
polysensitized, except patient #4 for whom no
sensitization was found. Total serum IgE ranged
from 141 to 8000 KUI/L.
Omalizumab was primarily introduced
because of the severe ocular involvement. It
was administered every 2 weeks by
subcutaneous injections, at doses varying from
450 to 600 mg per injection.
In three children (cases #1, 2 and 3), the
ocular response to omalizumab was graded as a
partial control: symptom scores dropped down
to values ranging from 30 to 52 mm at
8 weeks months and from 21 to 31 mm at the
end of follow-up. Clinical grading decreased
from grade 4 to grade 3 in these 3 cases (Fig. 1).
However, inflammatory flares with dense
punctate superficial keratitis (3–5 episodes per
year) still occurred but were much shorter and
easily controlled with topical steroids, which
were then only needed during the
inflammatory flares for a short course, and not
continuously as before omalizumab treatment.
Corneal inflammation returned to zero between
the inflammatory flares, which was never the
case before treatment. Topical cyclosporine was
continued in cases #1 and 2, and stopped in
case #3 because of allergy to the eye drops,
without consequence. No palpebral steroid
injections were needed in any of those three
cases.
In these three responder cases, asthma was
totally controlled after 4 months, and eczema
also healed completely after 9 months in case
#3. Rhinitis was only partially controlled, with
still noticeable nasal obstruction and
intermittent need for nasal steroids.
Omalizumab was stopped after 16 months in
case #1, and has been administered for 33 and
42 months, still ongoing in cases #2 and 3,
respectively.
Case #4 did not respond at all to
omalizumab, which was stopped after
6 months. Asthma and VKC still needed high












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pulses in order to control pulmonary and ocular
inflammation. Noticeably, this patient was the
only one to have no evident sensitization at
allergy workout. His serum IgE level was 141
pre-treatment, and 77 post-treatment.
Omalizumab was well tolerated in our four
patients, and no adverse effects were noted.
LITERATURE REVIEW
We performed a literature search in PubMed.
The keywords were vernal keratoconjunctivitis,
atopic keratoconjunctivitis, allergic
conjunctivitis, and omalizumab. There were
only case reports, with a total of four children
with VKC who were treated with omalizumab.
The cases are summarized in Table 1.
Sanchez et al. described the first VKC patient
treated with omalizumab in 2012 [18]. This
severe case had unsuccessfully been treated with
topical steroids/cyclosporine, then topical
tacrolimus 0.03% ointment for more than
2 years. Although this latter treatment had
been maintained, omalizumab clearly allowed
for a major reduction of the symptoms after
3–6 months, with a disappearance of the
conjunctival tarsal giant papillae after
10 months. No steroid treatment was needed
while on omalizumab. Extra ocular
involvement (asthma, atopic dermatitis and
rhinitis) also improved with the treatment.
The effects were still present after 18 months
of treatment.
In 2013, de Klerk et al. [15] described the
second case of VKC, who had developed a
corneal shield ulcer despite topical steroids on
the right eye, leading to a subtarsal injection of
triamcinolone. Omalizumab was introduced
because of non-controlled severe asthma and
rhinitis. After 2 months of treatment, ocular
Fig. 1 Patient #3, before treatment (a, b) and after
3 months of omalizumab (c). At month 4, a recurrence of
corneal inﬂammation occurred (d, e). Superior palpebral
conjunctival papillar hypertrophy (a, c) and corneal
ﬂuorescein staining (b, d, e), showing partial diminution
of inﬂammation. In this patient, several episodes of
corneoconjunctival inﬂammation occurred on omal-
izumab, but were less frequent and easier to control,
compared to before omalizumab treatment
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symptoms had improved, as well as asthma and
rhinitis. After 18 months, the ocular
involvement was completely controlled, with a
disappearance of the giant conjunctival papillae
and of the keratitis. Asthma and rhinitis were
completely controlled, although eczema was
still moderately active. Although this child had
had a severe corneal complication, it is difficult
to grade the real severity of his case, for topical
cyclosporine had been prescribed for a very
short time before omalizumab was initiated for
a non-ocular reason.
Recently, Heffler et al. reported two cases,
aged 9 (girl) and 21 (man) [19, 20]. The
particularities of their study are that none of
the patients had asthma, and the efficacy was
assessed by clinical parameters, but also by
eosinophil count on conjunctival scrape
smears. The cases were unresponsive to topical
corticosteroids, cyclosporine and tacrolimus,
and partially responsive to oral steroids. The
younger patient completely responded to
omalizumab within 2 months in terms of
symptoms and eye redness. The older patient
only responded partially and progressively
within 5 months. He also suffered from
eczema, and, given his age, might have, in
fact, a frontier form between AKC and VKC. The
eczema was not modified by omalizumab. Giant
papillae disappeared after 6 months in both
cases. The eosinophil count on conjunctival
smears was also dramatically reduced after
6 months of treatment, from 69% in the child
and 51% in the young man to 3% and 0%,
respectively. Omalizumab was stopped after
6 months in both cases, without recurrence
after 4 months.
Williams et al. published an expert review in
2005, where they reported six patients with
severe AKC [21]. Unfortunately, the description
of their cases was incomplete. Although three
patients were qualified as VKC in their summary
table, it is likely that all patients were, in fact,
AKC patients, as stated in the text, for their age
ranged from 27 to 71 years. All patients were on
topical and systemic steroids. It seems that
symptoms and signs decreased globally,
although some fluctuation was noted,
following the evolution of the general allergy
symptoms. The need for topical steroids was
decreased in all patients but one. No patient
received topical cyclosporine.
DISCUSSION
Omalizumab seems to be a potent treatment for
refractory forms of VKC. It allows a reduction of
symptoms and corneoconjunctival
inflammation. Its efficacy is, however, variable
among patients. One patient out of eight did
not respond at all. Response was considered as
partial in four patients, and complete in three.
This variability could reflect the incomplete
responsibility of IgE-mediated mechanisms in
VKC, as proposed in the new classification of
allergic eye diseases published in a position
paper of the European Academy of Allergy and
Clinical Immunology written by Leonardi et al.
[6]. Case #4, for whom omalizumab failed, was
the only child of our series without any allergic
sensitization. Absence of allergy might be a risk
factor of treatment failure, although the two
patients reported by Heffler et al. were also
non-allergic but responded well to the
treatment. Besides, elevated total IgE blood
levels did not seem to be a predictive factor of
ocular response in these patients.
In patients with very high inflammatory
levels, omalizumab may only have a partial
effect. However, the patients are very happy
with the treatment, because the inflammatory
flares become more seldom and easily
controlled with topical steroids (cases #1, 2
and 3) or antihistamines (cases #7 and 8).
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Patients #1, 2 and 3 also suffered from
rhinitis, which was only partially controlled by
omalizumab, whereas asthma and eczema
totally healed within 4 months. Omalizumab
might have a lower effect on the eyes and nose,
compared to the lungs and skin, although
patient #8 did not show any improvement of
his eczema on omalizumab. The mechanisms of
nasal and ocular inflammation may be more
IgE-independent than asthma and eczema.
Several questions remain concerning the
optimal therapeutic scheme in VKC patients.
The dosing of omalizumab varied from 300 mg
every month to 600 mg every 2 weeks, which
represents a four-fold variation between
different teams, but there are no data available
in these patients for a dose–effect relation.
Among all the publications, our patients
have the longest duration of treatment by
omalizumab, up to 42 months. However, VKC
is seasonal in 70% of patients, with an increase
of inflammatory flares between February and
October. It is not clear whether omalizumab
could be stopped during winter, but it seems
that this practice has been adopted by some
teams.
The cost of omalizumab remains a concern
(several thousand euros in Europe), but in most
severe cases of VKC, we believe that such a cost
is justified. Although the effect was partial in
our patients, the occurrence of severe corneal
complications was prevented, and the quality of
life of the patients much better. In the future,
other key mechanisms such as those involving
eosinophils should be targeted by new
treatments.
CONCLUSION
Omalizumab is an interesting treatment for
refractory forms of VKC. Its efficacy can be
partial in most severe forms, but reduction of
signs, symptoms and anti-inflammatory
treatment is almost always noted. The best
patient profile and treatment regimen are yet
to be determined. Controlled studies are needed
in the future.
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